Proteomic analysis of pancreatic ductal carcinoma cells after combined treatment with gemcitabine and trichostatin A

Journal of Proteome Research

Volumn 4, Issue 6, 2005, Pages 1909-1916

  Cecconi, Daniela ^a   Donadelli, Massimo ^a   Scarpa, Aldo ^a   Milli, Alberto ^a   Palmieri, Maria ^a   Hamdan, Mahmoud ^b   Areces, Liliana B ^c   Rappsilber, Juri ^c   Righetti, Pier Giorgio ^a,d  

^a UNIVERSITY OF VERONA   (Italy)

^b GSK   (Italy)

^c FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^d POLITECNICO DI MILANO   (Italy)

Author keywords

Ductal carcinomas; Gemcitabine (2 ,2 difluorodeoxycytidine); Pancreatic tumors; Proteomics; Trichostatin A

Indexed keywords

ANTINEOPLASTIC AGENT; CALCYCLIN; CHAPERONE; CYCLOPHILIN; CYTOKERATIN; ENOLASE; GALECTIN 1; GEMCITABINE; GLUTATHIONE TRANSFERASE; GUANINE NUCLEOTIDE BINDING PROTEIN BETA SUBUNIT; HEAT SHOCK PROTEIN; HISTONE DEACETYLASE INHIBITOR; HISTONE H2A; ISOMERASE; LIPOCORTIN 1; LIPOCORTIN 2; MIGRATION INHIBITION FACTOR; PEROXIREDOXIN; PROFILIN; PROLACTIN RELEASING FACTOR; PROTEIN; PROTEIN 14 3 3; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; RNA BINDING PROTEIN; STATHMIN; SUPEROXIDE DISMUTASE; THIOREDOXIN; TRICHOSTATIN A; TRIOSEPHOSPHATE ISOMERASE; UBIQUITIN CONJUGATING ENZYME;

APOPTOSIS; ARTICLE; CANCER CELL; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; ELECTROSPRAY MASS SPECTROMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; PANCREAS CARCINOMA; PANCREAS DUCT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; TREATMENT OUTCOME; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXAMIC ACIDS; INHIBITORY CONCENTRATION 50; MASS SPECTROMETRY; PEPTIDES; PROTEIN BINDING; PROTEIN SYNTHESIS INHIBITORS; PROTEINS; PROTEOME; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TIME FACTORS;

EID: 29144492905     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr050154j     Document Type: Article

References (46)

1. Jain, K. K. Applications of proteomics in oncology. Pharmacogenomics 2000, 1, 385-393.
2. Righetti, P. G.; Castagna, A.; Antonioli, P.; Cecconi, D.; Campostrini, N.; Righetti, S. Proteomics and oncology: some new insight on chemoresistance of tumour cells. Expert Rev. Proteomics 2005, 2, 215-228.
3. Petricoin, E. F.; Zoon, K. C.; Kohn, E. C.; Barrett, J. C.; Liotta, L. A. Clinical proteomics: translating benchside promise into bedside reality. Nat. Rev. Drug Disc. 2002, 1, 683-695.
4. Petricoin, E. F.; Wulfkuhle, J.; Espina, V.; Liotta, L. A. Clinical proteomics: revolutionizing disease detection and patient tailoring therapy. J. Proteome Res. 2004, 3, 209-217.
5. Weston, A. D.; Hood, L. Systems biology, proteomics and the nature of health care: towards predictive, preventive and personalized medicine. J. Proteome Res. 2004, 3, 179-196.
6. Li, D.; Xie, K.; Wolff, R.; Abruzzese, J. L. Pancreatic cancer. Lancet 2004, 363, 1049-1057.
7. Haller, D. G. New perspectives in the management of pancreatic cancer. Semin. Oncol. 2003, 30, 3-10.
8. Raraty, M. G.; Magee, C. J.; Ghaneh, P.; Neoptolemos, J. P. New techniques and agents in the adjuvant therapy of pancreatic cancer. Acta Oncol. 2002, 41, 582-595.
9. Burris, H. A. 3rd; Moore, M. J.; Andersen, J. et al. Improvements in survival and clinical benefit with GEM as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997, 15, 2403-2413.
10. Plunkett, W.; Huang, P.; Gandhi, V. Preclinical characteristics of gemcitabine. Anticancer Drugs 1995, 6 Suppl 6, 7-13.
11. Plunkett, W.; Huang, P.; Xu, Y. Z.; Heinemann, V.; Grunewald, R.; Gandhi, V. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin. Oncol. 1995, 22, 3-10.
12. Moore, P. S.; Sipos, B.; Orlandini, S. et al. Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. Virchows Arch. 2001, 439, 798-802.
13. Galmarini, C. M.; Clarke, M. L.; Falette, N.; Puisieux, A.; Mackey, J. R.; Dumontet, C. Expression of a nonfunctional p53 affects the sensitivity of cancer cells to gemcitabine. Int. J. Cancer 2002, 97, 439-445.
14. Cascallo, M.; Calbo, J.; Gelpi, J. L.; Mazo, A. Modulation of drug cytotoxicity by reintroduction of wild-type p53 gene (Ad5CMV-p53) in human pancreatic cancer. Cancer Gene Ther. 2000, 7, 545-556.
15. Lund, A. H.; van Lohuizen, M. Epigenetics and cancer. Genes Develop. 2004, 18, 2315-2335.
16. Aparicio, A.; Weber, J. S. Review of the clinical experience with 5-azacytidine and 5-aza-2′-deoxycytidine in solid tumors. Curr. Opin. Investig. Drugs 2002, 3, 627-633.
17. Kelly, W. K.; O'Connor, O. A.; Marks, P. A. Histone deacetylase inhibitors: from target to clinical trials. Expert. Opin. Investig. Drugs 2002, 11, 1695-1713.
18. Fournel, M.; Trachy-Bourget, M. C.; Yan, T.; Kalita, A. et al. Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors. Cancer Res. 2002, 62, 4325-4330.
19. Batova, A.; Shao, L.; Diccianni, M. B.; Tanaka, T. et al. The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines. Neoplasia 2002, 100, 3319-3324.
20. Van Lint, C. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr. 1996, 5, 245-253.
21. Moore, P. S.; Barbi, S.; Donadelli, M.; Costanzo, C.; Bassi, C.; Palmieri, M.; Scarpa, A. Gene expression profiling after treatment with the histone deacetylase inhibitor trichostatin A reveals altered expression of both pro- and anti-apoptotic genes in pancreatic adenocarcinoma cells. Biochim. Biophys. Acta 2004, 1693, 167-176.
22. Donadelli, M.; Costanzo, C.; Fagioli, L. et al. Trichostatin A, an inhibitor of histone deacetylases, strongly suppresses growth of pancreatic adenocarcinoma cells. Mol. Carcinog. 2003, 38, 59-69.
23. Cecconi, D.; Scarpa, A.; Donadelli, M.; Palmieri, M.; Hamdan, M.; Aster, H.; Righetti, P. G. Proteomic profiling of pancreatic ductal carcinoma cell lines treated with trichonstatin-A. Electrophoresis 2003, 24, 1871-1878.
24. Righetti, P. G. Immobilized pH Gradients: Theory and Methodology, Elsevier: Amsterdam, 1990.
25. Berggren, K. N.; Schulenberg, B.; Lopez, M. F.; Steinberg, T. H.; Bogdanova, A., Smejkal, G.; Wang, A.; Patton, W. F. An improved formulation of SYPRO Ruby protein gel stain: comparison with the original formulation and with a ruthenium II tris (bathophenanthroline disulfonate) formulation. Proteomics 2002, 2, 486-498.
26. Horiguchi N, Arimoto K, Mizutani A, Endo-Ichikawa Y, Nakada H, Taketani S. Galectin-1 induces cell adhesion to the extracellular matrix and apoptosis of nonadherent human colon cancer Colo201 cells. J. Biochem. (Tokyo). 2003 134, 869-874.
27. Wang, L.; Friess, H.; Zhu, Z.; Frigeri, L.; Zimmermann, A.; Korc, M.; Berberat, P. O.; Buchler, M. W. Galectin-1 and galectin-3 in chronic pancreatitis. Lab. Invest. 2000, 80, 1233-1241.
28. Gillenwater, A.; Xu, X. C.; Estrov, Y.; Sacks, P. G.; Lotan, D.; Lotan, R. Modulation of galectin-1 content in human head and neck squamous carcinoma cells by sodium butyrate. Int. J. Cancer. 1998, 75, 217-224.
29. Sakaguchi, M.; Miyazaki, M.; Inoue, Y.; Tsuji, T.; Kouchi, H.; Tanaka, T.; Yamada, H.; Namba, M. Relationship between contact inhibition and intranuclear S100C of normal human fibroblasts. J. Cell. Biol. 2000 149, 1193-1206.
30. Memon, A. A.; Sorensen, B. S.; Meldgaard, P.; Fokdal, L.; Thykjaer, T.; Nexo, E. Down-regulation of S100C is associated with bladder cancer progression and poor survival. Clin. Cancer Res. 2005 11, 606-611.
31. Kim, H. J.; Chae, H. Z.; Kim, Y. J.; Kim, Y. H.; Hwangs, T. S.; Park, E. M.; Park, Y. M. Preferential elevation of Prx I and Trx expression in lung cancer cells following hypoxia and in human lung cancer tissues. Cell. Biol. Toxicol. 2003, 19, 285-298.
32. Mamidipudi, V.; Zhang, J.; Lee, K. C.; Cartwright, C. A. RACK1 regulates G1/S progression by suppressing Src kinase activity. Mol. Cell. Biol. 2004, 24, 6788-6798.
33. Ogata, M.; Naito, Z.; Tanaka, S.; Moriyama, Y.; Asano, G. Overexpression and localization of heat shock proteins mRNA in pancreatic carcinoma. J. Nippon Med. Sch. 2000, 67, 177-185.
34. Neckers, L.; Neckers, K. Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics-an update. Expert Opin. Emerg. Drugs 2005, 10, 137-149.
35. Frese, S.; Schaper, M.; Kuster, J. R.; Miescher, D.; Jaattela, M.; Buehler, T.; Schmid, R. A. Cell death induced by down-regulation of heat shock protein 70 in lung cancer cell lines is p53-independent and does not require DNA cleavage. J. Thorac. Cardiovasc. Surg. 2003, 126, 748-754.
36. Lee, C. S.; Montebello, J.; Rush, M.; Georgiou, T.; Wawryk, S.; Rode, J. Overexpression of heat shock protein (hsp) 70 associated with abnormal p53 expression in cancer of the pancreas. Zentralbl. Pathol. 1994, 140, 259-264.
37. Liu, B.; Staren, E. D.; Iwamura, T.; Appert, H. E.; Howard, J. M. Mechanisms of taxotere-related drug resistance in pancreatic carcinoma. J. Surg. Res. 2001, 99, 179-186.
38. Van Antwerp, D. J.; Martin, S. J.; Verma, I. M.; Green, D. R. Inhibition of TNF-induced apoptosis by NF-kappa B. Trends Cell. Biol. 1998, 8, 107-111.
39. Harris, S. L.; Levine, A. J. The p53 pathway: positive and negative feedback loops. Oncogene 2005, 24, 2899-2908.
40. Weydert, C.; Roling, B.; Liu, J.; Hinkhouse, M. M.; Ritchie, J. M.; Oberley, L. W.; Cullen, J. J. Suppression of the malignant phenotype in human pancreatic cancer cells by the overexpression of manganese superoxide dismutase. Mol. Cancer Ther. 2003, 2, 361-369.
41. Cullen, J. J.; Weydert, C.; Hinkhouse, M. M.; Ritchie, J.; Domann, F. E.; Spitz, D.; Oberley, L. W. The role of manganese superoxide dismutase in the growth of pancreatic adenocarcinoma. Cancer Res. 2003, 63, 1297-1303.
42. Ueda, S.; Nakamura, H.; Masutani, H.; Sasada, T.; Yonehara, S.; Takabayashi, A.; Yamaoka, Y.; Yodoi, J. Redox regulation of caspase-3(-like) protease activity: regulatory roles of thioredoxin and cytochrome c. J. Immunol. 1998, 161, 6689-6695.
43. Ueno, M.; Masutani, H.; Arai, R. J.; Yamauchi, A.; Hirota, K.; Sakai, T.; Inamoto, T.; Yamaoka, Y.; Yodoi, J.; Nikaido, T. Thioredoxin-dependent redox regulation of p53-mediated p21 activation. J. Biol. Chem. 1999, 274, 35809-35815.
44. Anderson, J. M.; Heindl, L. M.; Bauman, P. A.; Ludi, C. W.; Dalton, W. S.; Cress, A. E. Cytokeratin expression results in a drug-resistant phenotype to six different chemotherapeutic agents. Clin. Cancer Res. 1996, 2, 97-105.
45. Lodygin, D.; Diebold, J.; Hermeking, H. Prostate cancer is characterized by epigenetic silencing of 14-3-3 sigma expression. Oncogene. 2004, 23, 9034-9041.
46. Alli, E.; Bash-Babula, J.; Yang, J. M.; Hait, W. N. Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer. Cancer Res. 2002, 62, 6864-6869.